The homeodomain protein Meis1 is essential for definitive hematopoiesis and vascular patterning in the mouse embryo  by Azcoitia, Valeria et al.
www.elsevier.com/locate/ydbioDevelopmental BiologyThe homeodomain protein Meis1 is essential for definitive hematopoiesis
and vascular patterning in the mouse embryo
Valeria Azcoitia, Miguel Aracil, Carlos Martı´nez-A, Miguel TorresT
Departamento de Inmunologı´a y Oncologı´a, Centro Nacional de Biotecnologı´a/CSIC UAM Campus de Cantoblanco, E-28049 Madrid, Spain
Received for publication 21 August 2004, revised 4 December 2004, accepted 5 January 2005Abstract
Homeodomain proteins of the Meis subfamily are expressed dynamically in several organs during embryogenesis and exert potent
regulatory activity through their interaction with Hox proteins and other transcription factors. Here we show that Meis1 is expressed in the
hematopoietic stem cell (HSC) compartment in the fetal liver, and in the primary sites of definitive hematopoiesis, including the aorta–
gonad–mesonephros (AGM) mesenchyme, the hemogenic embryonic arterial endothelium, and hematopoietic clusters within the aorta,
vitelline, and umbilical arteries. We inactivated the Meis1 gene in mice and found that Meis1 mutant mice die between embryonic days 11.5
and 14.5, showing internal hemorrhage, liver hypoplasia, and anemia. In Meis1 mutant mouse fetal liver and AGM, HSC compartments are
severely underdeveloped and colony-forming potential is profoundly impaired. AGM mesenchymal cells expressing Runx1, an essential
factor for definitive HSC specification, are almost absent in mutant mice. In addition, hematopoietic clusters in the dorsal aorta, vitelline, and
umbilical arteries are reduced in size and number. These results show a requirement for Meis1 in the establishment of definitive
hematopoiesis in the mouse embryo.Meis1 mutant mice also displayed complete agenesis of the megakaryocyte lineage and localized defects
in vascular patterning, which may cause the hemorrhagic phenotype.
D 2005 Elsevier Inc. All rights reserved.
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Hematopoiesis is a fundamental process during embryo-
genesis and throughout life in most metazoans. In mammals,
the first signs of hematopoiesis appear in the extraem-
bryonic region, in areas of the yolk sac known as blood
islands. The progenitors of this first wave of primitive
hematopoiesis supply blood cells only for the initial stages
of embryonic development (Galloway and Zon, 2003). At
different locations in the embryo proper, definitive hema-
topoietic stem cells (HSC) sequentially appear in the
transitory hematopoietic organs of the fetus (yolk sac, liver,
and spleen) and finally, in the main hematopoietic organ of
postnatal life, the bone marrow (Godin and Cumano, 2002;
Robin et al., 2003). The first and major embryonic site in0012-1606/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: mtorres@cnb.uam.es (M. Torres).which HSCs are born is the aorta–gonad–mesonephros
(AGM) region (Godin et al., 1993; Medvinsky and
Dzierzak, 1996; Medvinsky et al., 1993). Around stages
E9–E10.5, HSCs are generated in this region from
endothelial cells in the ventral wall of the dorsal aorta,
forming cell clusters that are delivered into the circulation
(Dieterlen-Lievre and Martin, 1981; Garcia-Porrero et al.,
1995; Tavian et al., 1996). HSC might use the vascular
network or migrate through mesenchyme to reach and
colonize other hematopoietic organs, although initiation of
hematopoiesis could also take place autonomously in the
yolk sac (reviewed in Dzierzak, 2002).
The molecular program for primitive hematopoiesis
overlaps largely, but not completely, with that involved in
the establishment of definitive HSC. For example, the Runx1/
CBFh complex is specifically required to establish definitive
hematopoiesis in the embryo, but not for primitive hema-
topoiesis (Niki et al., 1997; Okuda et al., 1996; Wang et al.,280 (2005) 307–320
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Hox family homeodomain proteins have a particularly
interesting function. Many of the 39 Hox proteins encoded
in the four paralogous genetic complexes are involved in
hematopoietic system pathologies or in normal hematopoietic
development (van Oostveen et al., 1999). Loss-of-function
(lof) models only rarely have revealed critical roles for
specific Hox proteins in hematopoiesis (Lawrence et al.,
1997), probably due to the considerable redundancy among
members of this family. In contrast, gain-of-function models
show the powerful regulatory potential of this family during
hematopoietic system development (Kroon et al., 1998; Kyba
et al., 2002; Sauvageau et al., 1995, 1997; Thorsteinsdottir et
al., 1997). HoxB4, for example, is a very potent promoter of
HSC population expansion (Antonchuk et al., 2002),
although HoxB4-single or HoxB3/HoxB4-double knockout
mice show only minor defects in HSC expansion ability
(Bjornsson et al., 2003; Brun et al., 2004).
Hox protein activity requires and is modified by
interaction with cofactors of the Meis and Pbx homeodomain
subfamilies. Dimerization of a Hox protein with Meis or Pbx,
or trimeric association of a Hox protein with Meis and Pbx,
results in increased DNA affinity and target specificity, both
required for correct transcriptional regulation of Hox targets
(Mann and Affolter, 1998). Whereas there are 39 Hox
proteins, there are only three Meis and four Pbx genes;
elimination of a single Meis or Pbx protein may thus result in
the simultaneous alteration of several Hox protein functions.
Mice deficient for a single Pbx protein (Pbx1) show
multilineage hematopoietic defects not observed for a single
mutation in any Hox gene (DiMartino et al., 2001). In mouse
models, Meis1 overexpression is linked to induction of acute
myeloid leukemia (AML) in close cooperation with HoxA7
or HoxA9 and, less efficiently, to induction of acute
lymphoid leukemia (ALL) (Moskow et al., 1995; Nakamura
et al., 1996). Direct interaction between Meis1, Pbx2, and
HoxA9 proteins has been demonstrated in myeloid cells
(Shen et al., 1999) and Meis1 co-overexpression with
HoxA9 transforms myeloid precursors (Calvo et al., 2001;
Kroon et al., 1998). In man, Meis1 is overexpressed in most
AML (Afonja et al., 2000; Lawrence et al., 1999) and in
some types of ALL (Imamura et al., 2002; Rozovskaia et al.,
2001). Meis1 role during definitive hematopoiesis has been
suggested from its expression in the adult bone marrow and
fetal liver HSC compartment and in hematopoietic progen-
itor cells during in vitro hematopoiesis from embryonic stem
cells (Pineault et al., 2002). In addition, Meis1 is broadly
expressed during early embryogenesis in paraxial, inter-
mediate, and lateral plate mesoderm. During organogenesis,
Meis1 is expressed and has functional roles in many organs
and embryonic structures, such as developing eyes and limbs
(Mercader et al., 1999; Zhang et al., 2002).
We show here that Meis1-deficient mice die around mid-
gestation due to a general failure of definitive hematopoi-
esis. We provide evidence that Meis1 affects the birth and
establishment of the first definitive HSC in the mouseembryo. In addition, we report that Meis1 is required later
during differentiation of the megakaryocytic lineage, as well
as for correct patterning of the vascular network.Materials and methods
Recombination constructs and gene targeting in ES cells
Mouse BAC ES DNA pool (Down-to-the-well pools;
Genome Systems) was screened with murine Meis1-specific
primers. A positive BAC clone was identified and a 16-kb
fragment containing the 3V end region of theMeis1 gene was
subcloned into pBluescript (Stratagene). The long arm used
in the recombination construct is a 7.5-kb SmaI–SmaI
fragment excised from the BAC, containing the last exon of
Meis1 except its splicing acceptor. For the short arm, a 1.6-
kb fragment containing Meis1 exon 12 (alternative exon
present in mRNA coding for Meis1a isoform) was amplified
from the BAC clone using the primers (sense) 5V-CC-
GCTCGAGATAGACCAGTCCAACCGA-3V and (anti-
sense) 5V-ATAGTCGACCATGTAGTGCCACTGCCC-3V
and subcloned into pCRE-ERT2 (Feil et al., 1997). Exon
12 was fused in-frame to the coding sequence of the
modified estrogen receptor ligand-binding domain ERT2. A
2.7-kb fragment was then cleaved with XhoI/SalI and was
used as the short arm of the targeting construct.
A pACN vector (Bunting et al., 1999) was modified by
insertion of a thymidine kinase cassette 5V of the ACN
cassette, and of PmlI–NotI restriction sites 3V of the ACN
cassette. The short arm was subsequently inserted between
the TK and ACN cassettes, and the long arm in the PmlI site.
The targeting vector was linearized at the NotI site and
electroporated in ES cells as described (Torres, 1998). ES cell
clones were screened by PCR, amplifying WT band with
primers: sense: 5V-TGATATGCTTTGCTTTCTTGGTT-3V,
and antisense: 5V-GTACTTACTTCCCCCTGGCTTTC-3V;
and the KO band with primers: sense: 5V-TGATATGCTTT-
GCTTTCTTGGTT-3V, and antisense: 5V-CTACACATTTTC-
CCTG GTTCCTG-3V. Chimeric mice were generated by ES
cell aggregation and crossed with CD1 females. Cells and
mice were genotyped using the following primers: for band a,
5V-GATGGACAGCCAATGGGAGGT-3V and 5V-CCCCCT-
GGCTTTCGATTGGTT-3V; band b, 5V-TCTTTTGGCAC-
TATCTGTTGA-3V and 5V-CATTTTCCCTGGTTCCTGTC-
3V; band c, 5V-GCCTTCTTGACGAGTTCTTCTG-3V and
5V-GGCTTGAGGCTGACATTGGCA-3V; band d, 5V-GA-
TGGACAGCCAATGGGAGGT-3V and 5V-GGCTTGAG-
GCTGACATTGGCA-3V.
Flow cytometry and cell sorting
Fetal livers were dissected from E12.5 embryos. Embryos
were then genotyped using the amniotic membrane. Fetal
liver cells were dispersed by passage through a 26-G½
needle in PBS with 10% fetal calf serum (FCS). Antibodies
V. Azcoitia et al. / Developmental Biology 280 (2005) 307–320 309used in flow cytometry included CD45 (PE-labeled), Mac1
(biotin), CD19 (biotin), Ter119 (biotin), cKit (PE), Sca1
(FITC), and AA4.1 (biotin); all were from BD PharMingen
(San Diego, CA) except AA4.1 (kindly provided by M.A.
Rodrı´guez-Marcos). Biotin-conjugated antibodies were
detected by secondary staining with Streptavidin-SPRD
(Southern Biotechnology Associates Inc. Birmingham,
AL). Cells were analyzed in a BD-LSR (Becton Dickinson,
San Jose, CA) equipped with the CellQuestPro System (BD
Biosciences).
Cell suspensions from pooled wild-type (WT) E12.5 fetal
livers were stained with CD45 or cKit (PE), Sca1 (FITC),
and biotin-conjugated lineage antibodies: Ter119, CD4,
CD8, B220, Mac1, and Gr1 (BD PharMingen, San Diego,
CA). The Sca1+/cKit+/Lin, CD45+, and CD45 popula-
tions were sorted, cytospun onto a gelatin-treated slide, fixed
with 4% paraformaldehyde (PFA) for 5 min, and incubated
with anti-Meis1 (obtained in our laboratory, see below).
In vitro hematopoietic colony-forming assays
Fetal livers were removed from E12.5 embryos; yolk sacs
and AGM regions were dissected from E10.5 embryos. Cells
were dispersed and embryos genotyped as above. Cells (4 
104) resuspended in a 300-Al volume of supplemented
medium, mixed with 3 ml Methocult medium M3234 (Stem
Cell Technologies, Vancouver, Canada), supplemented with
10 ng/ml murine IL-3 (Biosource, Worcester, MA), 6 U/ml
eritropoyetin (Stem Cell Technologies), and 50 ng/ml murine
Stem Cell Factor (Biosource, Worcester, MA), and 1 ml
duplicates were dispensed into 35-mm gridded bottom plates
(Falcon, Plymouth, UK). Cultures were incubated (378C).
Colonies were scored on day 7 for CFU-GM and day 12 for
BFU-E and CFU-Mix and were identified by their morphol-
ogy and hemoglobin content.
Immunofluorescence
Embryos were dissected at different gestation stages and
fixed in 4% PFA overnight. Some were paraffin embedded,
sectioned, and hematoxylin–eosin stained for anatomical
and morphological studies. Other embryos were cryopre-
served, cut into 10-Am sections, and acetone-fixed (2 min,
208C). Antibodies used were rabbit polyclonal anti-Runx1
(Levanon et al., 2001), CD41 (Pharmingen), Gata1 (Active
Motif), PECAM (Pharmingen), and anti-Meis1 (generated
in our laboratory). Sections were counterstained with DAPI
or Hoechst 33258.
Anti-Meis1 antibody was generated by immunizing
rabbits with a synthetic peptide for Meis1 amino acids 28-
44 (HAARSMQPVHHLNHGPP).
Western blot
Pooled of wt, +/, and ko E10.5 embryos without head
were homogenized by passing through a 26G1/2 needle andwere lysed in Ripa buffer. Anti-Meis1 antibody was used at
a 1:800 dilution.
Southern blot
DNA was extracted from E11.5 embryos, genotyped by
PCR and digested overnight with restriction enzymes.
Restriction enzyme map was obtained from the public
C57BL/6 mouse genome sequence (http://www.genome.
ucsc.edu/) and confirmed by digestion of the 129sv BAC
clone from which the targeting construct was generated. The
probe was amplified by PCR from BAC DNA with primers
that recognize sequences between exons 10 and 12,
respectively, and confirmed by sequencing.Results
Meis1-deficient mice die at mid-gestation due to defects in
fetal hematopoiesis
We inactivated the Meis1 gene in mice by knocking-in
the modified estrogen receptor hormone-binding domain
ERT2 (Feil et al., 1997). We introduced the ERT2 domain
in-frame with the Meis1a isoform coding region, while
eliminating the Meis1b coding region (Fig. 1A). For the
knock-in (KI) targeting strategy we used the ACN cassette,
which excises itself after passage through spermatogenesis
(Bunting et al., 1999). PCR analysis of targeted allele
structure in chimeric, heterozygous and homozygous
animals shows that the strategy functioned as expected
(Fig. 1B). Southern blot analysis confirmed the structure of
the targeted allele and the absence of multiple insertions
(Figs. 1C and D). The resulting allele, Meis1aER, is
predicted to encode an inactive protein unless the synthetic
estrogen analog tamoxifen (TM) is present. The coding
region resulting from the KI was constructed in parallel as a
mini-gene and expressed in vitro in 3T3 fibroblasts.
Whereas the WT Meis1 protein is always nuclear in 3T3
cells, the Meis1aER form was found in the cytoplasm in the
absence of TM and in the nucleus in its presence (Fig. 1E).
In homozygous mutant mice, we do not detect nuclear
Meis1 protein by immunofluorescence (see for example,
Figs. 4D and 8C). Although a weak increase in the
cytoplasmic signal was observed in some tissues (see for
example, Fig. 8C) it was barely distinguishable from a
general cytoplasmic background present in all tissues. In
Western blot analysis, WT Meis1 protein was detected in
WT and heterozygous mice but not in homozygous mutants
(Fig. 1F). A protein band of the expected size for the
Meis1a–ERT2 fusion appeared specifically in heterozygous
and homozygous mutants, albeit at a much lower level than
the WT protein (Fig. 1F). The size of the WT Meis1 protein
detected in the Western blot corresponded to the Meis1a
isoform, suggesting this is the predominant isoform
expressed in E10.5 embryo trunks.
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fertile, with no obvious anomalies. At gestation day 10.5,
homozygous mutants showed no phenotypic alterations;
however, 4 of 18 Meis1aER homozygous embryos were
found dead at E11.5, 8/53 at E12.5, 7/12 at 13.5, and 14/16 atE14.5, and no live mutant fetus was ever found beyond ges-
tation day 14.5. Starting at day 11.5, internal hemorrhages in
the neural tube lumen were observed in 25% of homozygous
mutants and from day 12.5, hemorrhages were also seen in
dorsal trunk regions (Fig. 2A). From gestation day 12.5, liver
size was approximately 50% smaller than in controls, and
general pallor was evident in the mutant embryos (Fig. 2B).
Meis1 mutation reduces the HSC population in fetal liver
To determine whether liver hypoplasia was due to a
failure in the generation of hematopoietic lineages, we used
flow cytometry to determine the number of cells expressing
hematopoietic markers in E12.5 livers. Cells positive for the
pan-hematopoietic marker CD45, the monocyte/granulocyte
marker Mac-1, the B cell lineage marker CD19, and the
erythrocyte marker Ter119 were represented in equal
proportions in total liver cells from mutant and WT mice
(Fig. 3A). All lineages thus showed a similar reduction in
absolute numbers, corresponding to the smaller liver size
observed, which suggested impairment of HSC or early
common precursors. We therefore assessed the HSC
population by analyzing the Sca1+/cKit+/Lin and CD45+/
AA4.1+/c-Kit+ cell pools in E12.5 fetal liver. Mutant mice
showed lower numbers of these triple-stained cell popula-
tions, both relative to total liver cell number and in absolute
terms (Fig. 3A). The reduction in HSC marker-positive cells
was greater than that observed for any other fetal liver
hematopoietic cell population, suggesting that HSC estab-
lishment or function is specially sensitive to Meis1 loss.
Concurring with this result, whereas Meis1 protein is not
expressed in CD45 fetal liver cells and is expressed atFig. 1. Targeting strategy and expression of the Meis1 targeted allele. (A)
Shaded boxes represent coding regions, empty boxes represent non-coding
exonic regions. Wild-type genomic structure at the 3V of the Meis1 gene is
shown above, in parallel with the targeting construct and predicted
recombination events. The targeted allele and predicted protein output are
shown below. The primer pairs and amplified segments used to characterize
the modification are represented above the schemes (termed a–d). (B) PCR
amplifications of bands a–d from wild-type (WT), chimeric (Ch), hetero-
zygous (Het), and homozygous (Hom) mice. (C) Restriction map of the
Meis1 locus targeted area showing the restriction sites that define the bands
recognized by the probe. E: EcoRI; H: HindIII; B: BamHI; X: XhoI. (D)
Predicted sizes of the restriction fragments in WT and mutant alleles are
shown in the left table. Southern blots of genomic DNA from WT,
heterozygous, and homozygous mutant mice hybridized with the probe
shown in bCQ are shown on the right. The XhoI site introduced with the ERT2
fragment appears to be methylated, since the 8.4-kb fragment resulting from
this site usage is minoritary in the blots, while the 12.3 band resulting from
non-usage of this site is majoritary. The presence of this site and the precision
of LoxP site Cre-mediated recombination were confirmed by sequencing the
bdQ band defined in bAQ amplified from mutant mice. (E) Subcellular
localization of Meis proteins is shown in NIH 3T3 fibroblasts transfected
with either Meis1WT (left), Meis1ERT2 in the absence (middle) or presence
(right) of Tamoxifen. Meis proteins were detected using the anti-Meis1
antibody. (F) Western blots showingMeis protein detection in E10.5 embryo
trunks from WT, heterozygous, and homozygous mutants (left) and in 293T
cells transfected with Meis1a or with empty vector (F). In both cases the
Meis proteins were detected using the anti-Meis1 antibody.
Fig. 2. Meis1 mutant mice die at midgestation showing hemorrhage and
liver hypoplasia. (A) Representative WT and mutant embryos on different
days of embryonic development. (B) Comparison of WT and mutant livers
at E12.5 (left) and total liver cell counts for WT, heterozygous, and
homozygous Meis1 mutants (right).
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Sca1+/c-Kit+/Lin fetal liver cells expressed homogeneous
high levels of Meis1 protein (Fig. 3B).
Immunofluorescence of E12.5 liver sections shows that
Meis1 expression coincides extensively, although not com-
pletely, with CD41 expression (Figs. 4A–C). Whereas all
CD41-positive cells express Meis1, not all Meis1-positiveFig. 3. Alterations in fetal liver hematopoietic cell compartments. (A)
Relative frequencies of cells expressing several hematopoietic markers.
Frequency of positive cells relative to total liver cell counts is shown above
and abundance per individual is shown below. Results were scored for
single individuals (each represented by a dot), normalized to the average
result for WT embryos in each litter, and expressed as a percentage. (B)
Immunofluorescence using anti-Meis1 antibody on sorted CD45+, CD45,
and Sca-1+/c-Kit+/Lin cells. Meis staining is shown in red, alone (right) or
in combination with DAPI in blue (left).
Fig. 4. Characterization of fetal liver phenotype by immunofluorescence. Images show staining in red for Meis1 (A, D), Runx1 (G, J), and Gata-1 (M, P), green
for CD41 (B, E, H, K, N, Q) and merged with DAPI in blue (C, F, I, L, O, R), on wild-type (A–C, G–I and M–O) and mutant (D–F, J–L and P–R) E12.5 fetal
liver sections.
V. Azcoitia et al. / Developmental Biology 280 (2005) 307–320312
V. Azcoitia et al. / Developmental Biology 280 (2005) 307–320 313cells express CD41. CD41 represents the alpha-IIb integrin
subunit, whose expression at high levels correlates with
cells of the megakaryocyte lineage; CD41 expressed at low
levels correlates with long-term-repopulating (LTR) hema-
topoietic cells during embryonic definitive hematopoiesis
(Ferkowicz et al., 2003; Mikkola et al., 2003). In Meis1
mutant mice, CD41 expression in fetal liver is almost
completely absent, with very few cells expressing low CD41
levels (Figs. 4D–F).
CD41 expression is regulated directly by Runx1 and
GATA-1 in the megakaryocyte lineage (Elagib et al., 2003)
and requires Runx1 and SCL (Stem Cell Leukemia) tran-
scription factors in embryonic hematopoietic precursors
(Mikkola et al., 2003). Similar to Meis1, Runx1 expression
correlates extensively, but not completely with CD41
expression in the E12.5 fetal liver (Figs. 4G–I). In mutant
mice, the Runx1-positive cell population is greatly dimin-
ished compared to controls, although expression levels in
individual cells remain unmodified (Figs. 4J–L). GATA-1,
which is involved in erythroid/megakaryocytic lineage
development (Pevny et al., 1991), is also co-expressed with
CD41 in many liver cells (Figs. 4M–O); in contrast to Runx1,
a homogeneous reduction in GATA-1 expression level was
found in Meis1 mutant fetal liver cells (Figs. 4P–R).
The results show that Meis1 is essential for fetal liver
hematopoiesis, affecting the generation of all differentiating
populations equally, but specially depleting the cell com-
partment expressing HSC markers.
Meis1 mutation impairs hematopoiesis in the AGM region
and umbilical and vitelline arteries
We characterizedMeis1 expression in the regions in which
definitive HSC first appear in embryonic development; the
AGM, and the vitelline and umbilical arteries. We used
Runx1, which is necessary for the generation of definitive
HSC in these regions, as a specific nuclear marker for cells
with long-term repopulation (LTR) potential (Lacaud et al.,
2002; Mukouyama et al., 2000; North et al., 2002; Yokomizo
et al., 2001). We also analyzed expression of PECAM
(CD31), which labels both endothelial cells as well as HSC
in intra-arterial hematopoietic clusters and throughout ontog-
eny (Baumann et al., 2004; Cai et al., 2000; Garcia-Porrero et
al., 1998), and CD41, whose expression is associated with
hematopoietic progenitors in the embryo (Ferkowicz et al.,
2003; Mikkola et al., 2003; Mitjavila-Garcia et al., 2002).
Meis1 expression was detected in the mesenchyme surround-
ing the embryonic dorsal aorta (Fig. 5A). In this region,
Runx1 was strongly expressed in a layer of two/three-cell
thickness adjacent to aorta endothelial cells, whereas
PECAM and CD41 were not expressed in mesenchymal
cells (Fig. 5B and not shown). In Meis1 mutants, few or no
Runx1-expressing cells were observed in the mesenchyme
(Fig. 5C).
In general, Runx1 was not expressed in endothelial cells,
but high levels were found in rounded PECAM-expressingcells within the endothelial layer that began to bulge from
the endothelium, prefiguring hematopoietic clusters (Figs.
5B and 6B). The Meis1 expression pattern was similar; it
was not widely expressed in endothelial cells but appeared
in cells bulging from the endothelium in the ventral portion
of the dorsal aorta (Figs. 5A and 6A). We did not detect
CD41 expression in Runx1- and Meis1-expressing cells in
the ventral aorta endothelium (not shown). Meis1 mutants
show almost complete absence of Runx1-expressing cells in
the aorta endothelial layer.
The hematopoietic clusters inside the aorta, vitelline, and
umbilical arteries are identified by Runx1 expression; they
are strongly positive for PECAM and weakly positive for
CD41 (Figs. 5E,H and 6B,E). All cells in hematopoietic
clusters in these three arteries also showed high Meis1
expression levels (Figs. 5D,G and 6A,D). In Meis1 mutant
mice, the hematopoietic clusters inside these arteries were
considerably fewer in number and smaller in size than in
controls, as identified by PECAM+Runx1 or Runx1+CD41
expression (Figs. 5F,I and 6C,F). Cells in the few hema-
topoietic clusters detected in mutant mice conserved normal
PECAM expression levels but showed very little or no CD41
expression (Figs. 5F,I and 6C,F). Cells in hematopoietic
clusters in mutant mice generally showed normal Runx1
expression, although individual cells in some clusters did not
express Runx1 (Fig. 6C), a phenomenon not observed in
wild-type mice. These results indicate that Meis1 mutant
mice show defective hematopoiesis in the dorsal aorta,
vitelline, and umbilical arteries. In addition, Meis1 appears
to be essential for CD41 expression in hematopoietic
clusters, but not for PECAM or Runx1 expression.
We analyzed the in vitro function of hematopoietic pre-
cursors from various embryonic sources in a colony assay.
Dispersed cells from different embryonic regions were plated
in semi-solid medium that promotes simultaneous growth
of erythroid (BFU-E), myeloid (CFU-GM), and mixed
(CFU-Mix) hematopoietic cell colonies. Mutant E12.5 fetal
liver cells were notably impaired in their ability to form
CFU-GM and BFU-E colonies and were practically unable
to generate CFU-Mix colonies (Fig. 7A). Similar results were
obtained with cells from E10.5 yolk sacs and AGM, except
that CFU-GM appeared to be less affected (Figs. 7B and C).
Meis1 is essential for development of the megakaryocyte
lineage
We found strong Meis1 expression in WT liver (Figs.
4A–C) and circulating cells (Fig. 8A) that were identified
as megakaryocytes and their precursors by morphological
criteria and by CD41 expression. In contrast, Meis1 was
not detected in terminally differentiating megakaryocytes
(Fig. 8B). In WT mice, megakaryocyte precursors in fetal
liver and in circulation were identified by intense CD41
expression (Figs. 4C and 8A). In addition, numerous
circulating platelets can be detected in large vessel or
heart sections with the CD41 marker (Fig. 8B). We
Fig. 5. Alterations in hemogenic activity of AGM, and vitelline and umbilical arteries. Images show antibody staining of cryostat sections from wild-type (A, B,
D, E, G, H) and mutant embryos (C, F, I). Sections show (A–C) the AGM at the insertion of the vitelline artery (Va) to the dorsal aorta (Ao), (D–F) the proximal
end of the umbilical artery (Ua), and (G–I) the vitelline artery (Va). Sections were triple stained with anti-Meis1 (A, D, G) or -Runx1 (B, C, E, F, H, I) in red,
anti-PECAM in green, and nuclei stained with Hoechst in blue (all images). Meis1- or Runx1-positive nuclei are pink, resulting from colocalization of blue and
red stains. PGCs: primordial germ cells (positive for PECAM staining).
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entiation of the megakaryocyte lineage in mutant mice.
Megakaryocyte precursors were absent in fetal liver of
Meis1 mutants, as judged by morphological criteria and
by lack of CD41-positive cells (Figs. 4D–F and not
shown), and circulating megakaryocytes were virtually
undetectable in mutant embryos (Fig. 8C). Furthermore,
no platelets were found using the CD41 marker in any
large vessel or heart section of the mutants (Fig. 8C). The
results indicate that lack of Meis1 function impairsmegakaryocyte lineage development, leading to platelet
agenesis in the mutant embryo.
Meis1 is required for correct vascular network formation in
the embryo
One of the most obvious consequences of Meis1
deficiency is internal hemorrhage. Hemorrhages were found
most frequently in the neural tube lumen from stage E11.5,
and in the trunk flank near the regions of limb insertion and
Fig. 6. Meis1 is required for hematopoietic cluster development and CD41 expression in HSC. Images show antibody staining of cryostat sections from wild-
type (A, B, D, E) and mutant embryos (C, F). Sections show (A–C) intra-arterial hematopoietic clusters at the dorsal aorta (Ao) and (D–F) the proximal end of
the umbilical artery (Ua). Sections were triple-stained with anti-Meis1 (A, D) or -Runx1 (B, C, E, F) in red, anti-PECAM (A–C) or -CD41 (D–F) in green, and
nuclei stained with Hoechst in blue (all images). Meis1- or Runx1-positive nuclei are pink, resulting from colocalization of blue and red stains. Arrows indicate
hematopoietic clusters or hemogenic endothelial cells. Arrowheads indicate non-hemogenic endothelial cells. Asterisk indicates a Runx1-negative cell in a
hematopoietic cluster.
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determine whether hemorrhage resulted from alterations in
vascular network development, we analyzed expression of
the endothelial marker PECAM in the affected regions at
E11.5, the first stage at which hemorrhage was observed.
We detected no obvious vascular defect associated with the
neural tube region (not shown). In contrast, in the
mesenchymal region at the trunk flanks, large vascular
sinuses accumulating blood cells were observed in mutants
(Fig. 9B), rather than the normal capillary network seen in
wild-type mice (Fig. 9A). Similar alterations were observed
at E12.5, with no signs of a break in the integrity of the
endothelial wall (Figs. 9C and D). After E12.5, however,
extravasated blood cells were found among the mesenchy-
mal cells in embryo flanks (not shown).Discussion
A new Meis1 mutant model
Meis1 is broadly expressed during early embryogenesis
in paraxial, intermediate, and lateral plate mesoderm.During organogenesis, Meis1 is expressed and has func-
tional roles in many organs and embryonic structures, such
as developing eyes and limbs (Mercader et al., 1999; Zhang
et al., 2002). Here we analyze the hematopoietic system
alterations observed in Meis1 mutants. Although detailed
analysis of defects in other organs has not yet been done,
obvious anomalies have not been detected in limb, eye,
hindbrain, or skeletal patterning. In a distinct Meis1 mutant
model recently reported (Hisa et al., 2004), defects similar
to those described here were found in fetal liver hema-
topoiesis. These two mutants were obtained using different
targeting strategies; whereas Hisa et al. produced a partial
Meis1 deletion, leaving a truncated Meis1 protein that is
expressed in mutant mice and could function as a dominant-
negative form (Hisa et al., 2004), we replaced Meis1 with an
inactive protein through fusion to the ERT2 domain. Both
mutants nonetheless show very similar hematopoietic
system defects and hemorrhage, suggesting that a similar
lof phenotype has been induced in both cases.
In contrast, there are discrepancies in other phenotypic
aspects of these mice. Whereas no obvious anomalies were
observed in the visual system of Meis1aER mice, Hisa et al.
found gross defects in eye development. It is possible that
Fig. 7. Impairment of in vitro hematopoietic colony formation activity from
Meis1 mutant embryos. The graphs show the number of CFU-GM, BFU-E,
and CFU-Mix obtained fromWTandmutant fetal liver (A), yolk sac (B), and
AGM (C). Each dot represents the number of colonies per embryo; horizontal
bars indicate the average number in each experimental group. The scale (1–5)
on the right of graph A refers only to CFU-Mix colonies.
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al. mutant is determinant in producing the eye phenotype
but has no major influence on other systems.
Our mutant model expresses an inactive protein from
the endogenous Meis1 locus, whose activity can be
switched on by tamoxifen. Similar approaches have been
used in mouse and Xenopus models (Pelengaris et al.,
1999; Tada et al., 1998; Zeisig et al., 2004), but this is its
first reported use as a knock-in strategy. The approach
appears efficient to generate protein loss of function in
agreement with previous reports using this domain. In
future studies, tamoxifen-induced conditional rescue of
Meis1 activity might allow further insight into Meis1
function and targets; however, our extensive efforts to
rescue the mutant phenotype administering tamoxifen
during the gestation of Meis1aER homozygous embryos
have failed. In all cases we reached abortive dosages of
tamoxifen before any significant rescue was observed. The
lower expression of the mutant protein as compared with
the WT protein or the inability of the mutant protein to
perform its functions even in the presence of tamoxifen
might explain these results. Alternatively, the Meis1b
isoform, deleted in the Meis1aER mutant, even though it
is not predominant at E10.5, might be necessary for Meis1
function in hematopoiesis. We are currently generating a
mutant Meis1bER mutant with which we will be able to
test this hypothesis.
Meis1 is required for the generation of definitive embryonic
HSC
We present evidence that the fetal hematopoietic failure
in Meis1 mutants is multilineage and specially affects cells
expressing HSC markers, suggesting a requirement for
Meis1 to establish definitive HSC in the embryo. Meis1 is
expressed in the AGM mesenchyme, in the hemogenic
embryonic arterial endothelium, and in the hematopoietic
clusters within the arteries. At these locations in the AGM,
only those cells expressing Runx1 have LTR-HSC activity
(North et al., 2002) and such cells are rare or absent in
Meis1 mutants, suggesting an important role for Meis in the
generation of definitive HSCs at these regions. Meis1
function is relevant to all three Runx1-expressing popula-
tions since in the mutants we found impaired Runx1
expression in AGM mesenchymal cells, many fewer
Runx1-expressing cells in endothelium, and very few, small
intra-arterial hematopoietic clusters. The sustained Meis1
expression during generation of hematopoietic arterial
clusters, the reduced cluster size, and the lack of Runx1
expression in some cells of the hematopoietic clusters
suggest multilevel Meis1 involvement in the generation of
intra-aortic hematopoietic clusters. While it is well estab-
lished that intra-aortic hematopoietic clusters derive from
the hemogenic endothelium (Jaffredo et al., 2000), the
relationship between the hemogenic endothelium and
Runx1-expressing mesenchymal cells remains unknown
Fig. 8. Megakaryocyte lineage impairment inMeis1 mutant embryos. Images show triple staining of cryostat sections with anti-Meis1 (red), anti-CD41 (green),
and DAPI (blue). Circulating megakaryocytes (A) and platelets in a heart section (B) are detected in WT embryos (A, B). Neither megakaryocytes nor platelets
are detected in heart sections of mutant embryos (C). Meis1-positive nuclei are pink as a result of colocalization of blue and red stains. Note the lack of Meis1
signal in mutant embryo heart cells. Arrowheads indicate circulating platelets.
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mesenchymal Runx1-positive cells, although the contribu-
tion of this population to HSC generation in vivo and its
lineage relationship to the hemogenic endothelium remains
to be determined.
Although they are very scarce, the Runx1-expressing
cells in mutant AGM and fetal liver nonetheless show
normal expression levels. This suggests that Meis1 is not
directly responsible for Runx1 expression, but rather for the
specification or survival of cells committed to its expres-Fig. 9. Vascular defects in Meis1 mutant embryos. The vascular network is
shown by anti-PECAM staining (green) on cryostat sections from the
dorsolateral trunk mesenchyme from WT (A) and mutant (B) E11.5
embryos. Histological sections of the same region are shown from WT (C)
and mutant (D) E12.5 embryos.sion. The situation is similar for PECAM, whose levels are
maintained in mutant intra-aortic hematopoietic clusters. In
contrast, CD41 expression is much lower in liver, AGM,
and circulating cells in Meis1 mutants, showing a strict
Meis1 requirement for CD41 expression. Runx1 regulates
the CD41 promoter directly (Elagib et al., 2003), and the
two factors may thus collaborate to regulate CD41. Other
critical targets in HSC generation nonetheless remain to be
identified, since CD41 is not required for embryonic
definitive hematopoiesis (Tronik-Le Roux et al., 2000).
Although Meis1 clearly impairs AGM hematopoiesis, the
penetrance of the mutant phenotype is incomplete since
some hematopoietic clusters are produced. In fact CFU-GM
formation potential is quite conserved in AGM and yolk sac
at E10.5 and only appears strongly impaired in E12.5 fetal
livers, suggesting that some definitive early populations are
born but fail to be expanded later in fetal hematopoiesis.
While Meis1 is the only member of its family expressed in
hematopoietic cell progenitors, it is co-expressed with the
related Meis2 protein in AGM mesenchyme. This may lead
to functional redundancy, which would account for the
incomplete penetrance of the phenotype. The role of Meis1
in embryonic definitive HSC generation concurs with the
reported inability of Meis1 mutant fetal liver cells to
repopulate any hematopoietic lineage after transplant (Hisa
et al., 2004). Meis1 role in definitive hematopoiesis might
extend into adult stages since its expression has been
reported in the bone marrow HSC compartment (Pineault
et al., 2002).
Meis1 and the development of the megakaryocyte lineage
In addition to its role in definitive hematopoiesis
establishment, Meis1 is also required during megakaryo-
cytic lineage development (Hisa et al., 2004 and this
study). GATA-1 and Runx1 are essential factors for
megakaryocyte development (Elagib et al., 2003) and thus
impaired GATA-1 and Runx1 expression in mutant fetal
liver may contribute to this phenotype. The Runx1 and
SCL (stem cell leukemia) transcription factors are both
V. Azcoitia et al. / Developmental Biology 280 (2005) 307–320318involved in HSC specification (Okuda et al., 1996; Robb et
al., 1995) and have a specific later role in megakaryocytic
lineage development (Elagib et al., 2003; Hall et al., 2003;
Ichikawa et al., 2004). The alpha-IIb integrin (CD41) is
also expressed in hematopoietic progenitors in the embryo,
specifically marks the megakaryocytic lineage during
hematopoietic differentiation, and requires both Meis1
and Runx1 activity to be expressed. These data suggest a
regulatory network essential for definitive HSC establish-
ment in the embryo, which is at least partially re-used
during megakaryocytic lineage development.
Meis1 and vascular patterning
Hisa et al. reported defects in microvasculature in E13.5
embryos, 2–3 days after the first hemorrhages and hema-
topoietic defects are detected in both Meis1 mutant models.
We found alterations in trunk vascular patterning at E11.5,
just before hemorrhage was first observed in this region. The
type of hemorrhage and stage at which it occurs are
strikingly similar to those reported for mutations in Runx1
and its functional partner, CBFh (Niki et al., 1997; Okuda et
al., 1996; Wang et al., 1996). Whereas Runx1 and CBFh are
not directly involved in vascular development and are not
generally expressed in the endothelium, HSC are necessary
for correct stimulation of angiogenesis. Lack of definitive
HSC in these mutants may thus account for the angiogenesis
defects (Takakura et al., 2000). A similar mechanism can be
invoked to explain vascular alterations in Meis1 mutants,
although given its extensive expression in the AGM and
lateral plate mesoderm, a direct role cannot be excluded for
Meis1 in the endothelial-mesenchymal interactions required
for correct vascular patterning. Nonetheless, since Meis1 and
Runx1/CBFh are implicated in megakaryocyte/platelet
development and the hemorrhage patterns are similar, we
consider that the lack of platelet function may also contribute
to this phenotype. Although there are several other mutants
with impaired platelet function or production that survive to
postnatal stages, in general they have not been studied for
platelet presence or function during embryogenesis.
Meis1 and the Hox network in hematopoietic development
Meis proteins dimerize with Pbx proteins, and hetero-
dimer formation is thought to be a requirement for the
function of both. Pbx1 is expressed in coordination with
Meis1 in the proximal limb and is proposed to be a partner
of Meis1 in this and other embryonic structures (Gonza´lez-
Crespo et al., 1998; Mercader et al., 1999). Pbx1 mutant
mice show mild defects at several steps in fetal hematopoi-
esis, although these alterations do not affect HSC specifi-
cally; Pbx1 mutants thus share few of the defects observed
in Meis1 mutant mice (DiMartino et al., 2001). In addition,
the Pbx1 mutants have axial skeleton and proximal limb
patterning anomalies not seen in Meis1 mutants (Selleri et
al., 2001). A strict partnership thus cannot be establishedbetween Meis1 and Pbx1; more likely, Meis-Pbx interaction
is promiscuous and a given Meis protein can interact with
different members of the Pbx family, depending on the
specific embryonic stage and tissue.
Modification of Hox protein activity frequently leads to
hematopoietic defects, both in mice and man (van Oostveen
et al., 1999). In most cases, the alterations that produce these
defects consist of hyperactivation or dominant changes in
Hox protein activity. In contrast, most Hox gene lof
mutations do not lead to major hematopoietic alterations.
A good example is the behavior of HoxB4, which strongly
enhances HSC specification and expansion when overex-
pressed (Kyba et al., 2002), but whose lof in mice provokes
only minor decreases in HSC expansion potential after
transplantation (Brun et al., 2004). This probably reflects
redundancy in Hox protein activity in hematopoiesis, since
HoxB3/HoxB4 double-deficient mice show enhanced, albeit
mild, HSC failure compared to the HoxB4 knockout mouse
(Bjornsson et al., 2003). The defects in Meis1 mutant mice
may result from functional impairment of several Hox
proteins with redundant functions in establishing the HSC
population. It is thus likely that Hox proteins other than
HoxB3 and HoxB4 are involved in this process, since the
Meis1 mutant phenotype is stronger than that of HoxB3/
HoxB4 mutant mice. Pbx1 represses HoxB4 HSC-promot-
ing activity, suggesting that Pbx1 and Meis1 might
antagonize each other in this process (Krosl et al., 2003).
For the promotion of definitive hematopoiesis, Meis1 could
thus function coupled to other Pbx proteins or, contrary to
current models, might operate independently of any Pbx
activity. We have studied the expression of the candidate
Meis1 cofactors of the Hox and Pbx families without
finding any significant alteration inMeis1 mutant mice (data
not shown). This result is the predicted by a model in which
Hox-Meis-Pbx interact strictly as cofactors. Under this
hypothesis, alterations would be expected to occur in the
expression of target genes of the Hox network; however, no
such targets have been identified yet in HSCs. Alternatively,
since both Meis and Pbx can also interact functionally with
other non-Hox transcription factors (Berkes et al., 2004;
Swift et al., 1998; Zhang et al., 2002), the role of Meis1 in
establishing HSC could be unrelated to Hox protein activity.Acknowledgments
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